Promedior Inc.
www.promedior.com
Latest From Promedior Inc.
Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
Roche Paying $390m Up Front For Fibrosis-Fighting Promedior
The deal, which includes up to $1bn for milestones, gives Roche Promedior’s PRM-151, a Phase III-ready asset for IPF that has also completed a Phase II study in myelofibrosis and could be effective in a broad range of fibrotic diseases.
Keeping Track: Approvals For Mayzent, Mavenclad, Duaklir, Jatenzo And Cimzia
The latest drug development news and highlights from our US FDA Performance Tracker.
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Company Information
- Industry
-
Biotechnology
- Large Molecule
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Hepatic (Liver)
- Ophthalmic
- Renal System
- Respiratory, Pulmonary
- Alias(es)
- Crovela BioPharm Inc.
- Medior Inc.
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Promedior Inc.
- Senior Management
-
Jason Lettmann, CEO
Richard L Jack, PhD, COO & CSO
Kieran McCarthy, VP, Bus. Dev. - Contact Info
-
Promedior Inc.
Phone: (781) 538-4200
101 Hartwell Ave.
Ste. 100
Lexington, MA 02421
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice